CD58 and type 1 diabetes mellitus: This pathway was subsequently further elucidated in T1DAL [Inducing Remission in Type 1 Diabetes with Alefacept (4)], in which a comparable group of T1D subjects received alefacept, a LFA3-Ig fusion protein targeting CD2.